(Stroke. 2000;31:1770.)
© 2000 American Heart Association, Inc.
Comments, Opinions, and Reviews |
Low-Molecular-Weight Heparins and Heparinoids in Acute Ischemic Stroke
A Meta-Analysis of Randomized Controlled Trials
From the Centre for Vascular Research, University of Nottingham, City Hospital Campus, Nottingham, UK.
Correspondence to Professor Philip Bath, Division of Stroke Medicine, University of Nottingham, City Hospital Campus, Hucknall Rd, Nottingham NG5 1PB, UK.
Background and Purpose—Low-molecular-weight heparins and heparinoids (LMWHs) are superior to unfractionated heparin in the prevention and treatment of venous thromboembolism and acute coronary syndromes. We performed a systematic review of randomized controlled trials (RCTs) to examine the safety and efficacy of LMWH in acute ischemic stroke.
Methods—Randomized, controlled, and nonconfounded trials of LMWH in acute ischemic stroke were identified from the Cochrane Library (version 2, 1999), previous systematic reviews, and a review of publication quality relating to acute stroke trials. The authors each independently extracted data by treatment group and assessed trial quality using Cochrane Collaboration criteria.
Results—Eleven completed RCTs involving 3048 patients were identified; data were available from 10 of these. Four trials explicitly excluded patients with presumed cardioembolic stroke. Treatment with LMWH was associated with significant reductions in prospectively identified deep vein thrombosis (OR 0.27, 95% CI 0.08 to 0.96) and symptomatic pulmonary embolism (OR 0.34, 95% CI 0.17 to 0.69) and with increased major extracranial hemorrhage (OR 2.17, 95% 1.10 to 4.28). Nonsignificant increases in end-of-treatment (OR 1.20, 95% CI 0.86 to 1.69) and end-of-trial (OR 1.05, 95% CI 0.83 to 1.32) case fatality and symptomatic intracranial hemorrhage (OR 1.77, 95% CI 0.95 to 3.31) were observed. End-of-trial death and disability was nonsignificantly reduced (OR 0.87, 95% CI 0.72 to 1.06).
Conclusions—LMWHs reduce venous thromboembolic events in patients with acute ischemic stroke and increase the risk of extracranial bleeding. A nonsignificant reduction in combined death and disability and nonsignificant increases in case fatality and symptomatic intracranial hemorrhage were also observed. On the basis of the current evidence, LMWH should not be used in the routine management of patients with ischemic stroke.
Key Words: deep vein thrombosis • embolism • heparin • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  K. W. Muir The PREVAIL Trial and Low-Molecular-Weight Heparin for Prevention of Venous Thromboembolism Stroke, July 1, 2008; 39(7): 2174 - 2176. [Full Text] [PDF]
|
|
|
|
|
|
M. Paciaroni, G. Agnelli, S. Micheli, and V. Caso Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials Stroke, February 1, 2007; 38(2): 423 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bates, J. Y. Choi, P. W. Duncan, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, D. Reker, and R. Zorowitz Veterans Affairs/Department of Defense Clinical Practice Guideline for the Management of Adult Stroke Rehabilitation Care: Executive Summary Stroke, September 1, 2005; 36(9): 2049 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Duncan, R. Zorowitz, B. Bates, J. Y. Choi, J. J. Glasberg, G. D. Graham, R. C. Katz, K. Lamberty, and D. Reker Management of Adult Stroke Rehabilitation Care: A Clinical Practice Guideline Stroke, September 1, 2005; 36(9): e100 - e143. [Full Text] [PDF]
|
|
|
|
 |
|
 P. M.W. Bath, L. Zhao, and S. Heptinstall Current status of stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C12 - C18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Leizorovicz and P. Mismetti Preventing Venous Thromboembolism in Medical Patients Circulation, December 14, 2004; 110(24_suppl_1): IV-13 - IV-19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Circulation, September 9, 2003; 108(10): 1278 - 1290. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Adams, M. I. Chimowitz, J. S. Alpert, I. A. Awad, M. D. Cerqueria, P. Fayad, and K. A. Taubert Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association Stroke, September 1, 2003; 34(9): 2310 - 2322. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Grotta Adding to the Effectiveness of Intravenous Tissue Plasminogen Activator for Treating Acute Stroke Circulation, June 10, 2003; 107(22): 2769 - 2770. [Full Text] [PDF]
|
|
|
|
 |
|
 A. I. Schafer, M. N. Levine, B. A. Konkle, and C. Kearon Thrombotic Disorders: Diagnosis and Treatment Hematology, January 1, 2003; 2003(1): 520 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, S. Palacio, and L. A. Pearce Atrial Fibrillation, Stroke, and Acute Antithrombotic Therapy: Analysis of Randomized Clinical Trials Stroke, November 1, 2002; 33(11): 2722 - 2727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick and W. Hacke Treatment of Acute Ischemic Stroke: Part II: Neuroprotection and Medical Management Circulation, September 24, 2002; 106(13): 1736 - 1740. [Full Text] [PDF]
|
|
|
|
|
|
C. Alonso-Ortiz del Rio, A. Romero-Alonso, I. Marin-Leon, M. Rincon-Gomez, and W. H. Geerts Strength of Evidence for Low-Molecular-Weight Heparin Chest, June 1, 2002; 121(6): 2078 - 2079. [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr Emergent Use of Anticoagulation for Treatment of Patients With Ischemic Stroke Stroke, March 1, 2002; 33(3): 856 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Strater, K. Kurnik, C. Heller, R. Schobess, P. Luigs, and U. Nowak-Gottl Aspirin Versus Low-Dose Low-Molecular-Weight Heparin: Antithrombotic Therapy in Pediatric Ischemic Stroke Patients: A Prospective Follow-Up Study Stroke, November 1, 2001; 32(11): 2554 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W Muir MEDICAL MANAGEMENT OF STROKE J. Neurol. Neurosurg. Psychiatry, April 1, 2001; 70(90001): 12i - 16. [Full Text]
|
|
|
|
 |
|
 What Is the Efficacy and Safety of LMWHs for Ischemic Stroke? Journal Watch Cardiology, November 9, 2000; 2000(1109): 11 - 11. [Full Text]
|
|
|
|
 |
|
 What Is the Efficacy and Safety of LMWHs for Ischemic Stroke? Journal Watch Neurology, October 5, 2000; 2000(1005): 9 - 9. [Full Text]
|
|